![Figure 1. Transcriptomic landscapes of CBF and RUNX1-CBFA2T3 AML. (A) Characteristics of CBF and non-CBF AML cohorts. (B-C) Comparative analyses of expressed genes in t(8;21) (B) and inv(16) (C) AML subgroups. Diamonds correspond to differentially expressed genes (difference ≥1 or ≤−1) listed in supplemental Tables 1 and 2 for panels B and C, respectively. Scales: mean{log10[(RPKM+0.0001)*10 000]}. (D) PCA performed in the Leucegene cohort (n = 415) using the 145-gene signature that characterizes AML with t(8;21)/RUNX1-RUNX1T1 (red dots). One sample with a t(16;21)/RUNX1-CBFA2T3 (lime green dot) clustered with t(8;21) AML. (E) PCA performed in the same cohort using the 127-gene signature that characterizes AML with inv(16)/CBFB-MYH11 (steel blue dots). A small constant of 0.0001 was added to all RPKM values prior to log10 transformation. FAB, French-American-British; RPKM, reads per kilobase per million mapped reads; T-AML, therapy-related AML; WBC, white blood cell.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/127/20/10.1182_blood-2016-03-703868/4/2498f1.jpeg?Expires=1724233051&Signature=q9-zDoOBucEjY-mjeonfNMFSkUziAUmobFCox49B4Gn64qwbuXeUNuY8NlapoONsuyTYNs2EtHl7PImJPsZ3MrPjQiMnFGUdDIhiP37H6hUjMbPxKYJMOVmOH51W-thbGlvNkZeJbALPBi9U4hbilAdL6DvaPtBDqzrpv7miGWK46shSY1wXbeIHAtPO3XiKTaXLu3fjsuoRzhKAWbWvknnCEVn~HAm1V8yRvUAVs7fd~MYcrXBwjU-8sW8izPODtzPgZQe1T3o-SGJIX3kW9AJtMLljgAdT3ExwIji3QyAtciMpoiV2tgNwyCKyGQLRes4tu-u--G8uIor1U~KW5w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Transcriptomic landscapes of CBF and RUNX1-CBFA2T3 AML. (A) Characteristics of CBF and non-CBF AML cohorts. (B-C) Comparative analyses of expressed genes in t(8;21) (B) and inv(16) (C) AML subgroups. Diamonds correspond to differentially expressed genes (difference ≥1 or ≤−1) listed in supplemental Tables 1 and 2 for panels B and C, respectively. Scales: mean{log10[(RPKM+0.0001)*10 000]}. (D) PCA performed in the Leucegene cohort (n = 415) using the 145-gene signature that characterizes AML with t(8;21)/RUNX1-RUNX1T1 (red dots). One sample with a t(16;21)/RUNX1-CBFA2T3 (lime green dot) clustered with t(8;21) AML. (E) PCA performed in the same cohort using the 127-gene signature that characterizes AML with inv(16)/CBFB-MYH11 (steel blue dots). A small constant of 0.0001 was added to all RPKM values prior to log10 transformation. FAB, French-American-British; RPKM, reads per kilobase per million mapped reads; T-AML, therapy-related AML; WBC, white blood cell.
